Ironwood Pharmaceuticals

IRWD on NASDAQ

Discovered linaclotide (Linzess) and shares US profits on it with AbbVie.

Share price

$3.82

Up 142% over 12 months

What analysts expect

Buy

Buy45%

Hold55%

Sell0%

Price target for the next 12 months

$6.23Up 75% compared with the current price

Price now $3.56Average targetLowest $3.70 to highest $10.00

7 analysts. 4 of the 7 analysts rate it Hold. Source: MarketBeat, 20 Oct 2026. Targets are opinions and are often wrong.

Business

Yearly revenue: $389M
Yearly profit: $130M
Company value: $631M
Forward P/E: 2.8×As of 2026-10-21
Forward P/S: 1.2×As of 2026-10-21

Revenue and profit for the last twelve months reported.

Forward P/E compares the share price with forecast earnings per share. Forward P/S compares company value with forecast revenue. Both are dated estimates, separate from the live price. Missing or non-positive estimates are shown as unavailable.

Peptides in this book

LinaclotidePrescription